Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108183 | 0.93 | CNR2 (0.40) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL13953641 | 0.90 | CNR2 (0.39) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL1170264 | 0.89 | NPC1 (0.45) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL13523178 | 0.89 | NPC1 (0.45) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL13521670 | 0.88 | KMT2A (0.36) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL1103767 | 0.88 | ALDH1A1 (0.41) | POLBALDH1A1LMNAGAAL3MBTL1 | |
| SCHEMBL8963242 | 0.86 | CNR2 (0.39) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL14706107 | 0.85 | MEN1 (0.36) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL1171548 | 0.84 | CNR2 (0.45) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL13521679 | 0.84 | SMN1; SMN2 (0.39) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188068-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8153617-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153618-B2 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | ALLACCEM, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | ALLACCEM, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100004218-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR RENAL THERAPY | ALLACCEM, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20090105262-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | ALLACCEM, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105262-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | PAICS, KRTCAP2, OSTC | MEN1 1137/4885KMT2A 2271/4885SMN1; SMN2 437/4885 |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | OTC, SLC16A8, SLC16A7 | MEN1 1095/4885KMT2A 2804/4885SMN1; SMN2 2897/4885 |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | PAICS, SLC16A8, CAD | MEN1 1262/4885KMT2A 855/4885SMN1; SMN2 1523/4885 |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | PCSK9, HMGCR, CETP | MEN1 766/4885KMT2A 2077/4885SMN1; SMN2 1707/4885 |
| US-20100004218-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR RENAL THERAPY | PKD1, PKD2, PAICS | MEN1 974/4885KMT2A 1243/4885SMN1; SMN2 1411/4885 |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | BMP2, BMP1, BMP6 | MEN1 2064/4885KMT2A 1766/4885SMN1; SMN2 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.